Explanation_NN of_IN transition_NN to_TO IFRS_NNP 137_CD EXPLANATION_NNP OF_IN TRANSITION_NNP TO_TO IFRS_NNP These_DT are_VBP the_DT Groups_NNS first_RB consolidated_JJ financial_JJ statements_NNS prepared_VBN in_IN accordance_NN with_IN IFRS_NNP ._.
The_DT accounting_NN policies_NNS set_VBN out_RP on_IN pages_NNS 87_CD to_TO 89_CD have_VBP been_VBN applied_VBN in_IN preparing_VBG the_DT Financial_NNP Statements_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD ,_, the_DT comparative_JJ information_NN presented_VBN in_IN these_DT financial_JJ statements_NNS for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2004_CD and_CC 31_CD December_NNP 2003_CD and_CC in_IN the_DT preparation_NN of_IN an_DT opening_NN IFRS_NNP balance_NN sheet_NN at_IN 1_CD January_NNP 2003_CD the_DT Groups_NNS date_NN of_IN transition_NN ._.
In_IN preparing_VBG its_PRP$ opening_NN balance_NN sheet_NN ,_, the_DT Group_NNP has_VBZ adjusted_VBN amounts_NNS reported_VBD previously_RB in_IN Financial_NNP Statements_NNP prepared_VBD in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
An_DT explanation_NN of_IN how_WRB the_DT transition_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP has_VBZ affected_VBN the_DT Groups_NNS financial_JJ position_NN ,_, financial_JJ performance_NN and_CC cash_NN flows_NNS is_VBZ set_VBN out_RP in_IN the_DT following_VBG tables_NNS and_CC the_DT notes_NNS that_WDT accompany_VBP the_DT tables_NNS ._.
The_DT information_NN below_IN differs_VBZ from_IN that_DT presented_VBN in_IN January_NNP 2005_CD in_IN the_DT 2004_CD Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ Information_NN in_IN that_DT certain_JJ income_NN statement_NN and_CC balance_NN sheet_NN items_NNS have_VBP been_VBN reclassified_VBN ._.
In_IN addition_NN ,_, as_IN noted_VBN in_IN the_DT accounting_NN policies_NNS on_IN page_NN 88_CD ,_, the_DT comparative_JJ information_NN has_VBZ also_RB been_VBN restated_VBN to_TO reflect_VB the_DT adoption_NN of_IN IAS_NNP 39_CD ,_, Financial_NNP Instruments_NNPS :_: Recognition_NN and_CC Measurement_NNP the_DT Fair_NNP Value_NNP Option_NN ._.
31_CD Dec_NNP 2004_CD 1_CD Jan_NNP 2003_CD Total_JJ equity_NN $_$ m_CD $_$ m_CD Total_JJ equity_NN under_IN UK_NNP GAAP_NNP 14,519_CD 11,226_CD Adjustments_NNS to_TO conform_VB to_TO IFRS_NNP Employee_NNP benefits_NNS 2,010_CD 1,380_CD Financial_NNP instruments_NNS 11_CD 153_CD Share-based_JJ payments_NNS Goodwill_NNP 108_CD Dividends_NNPS 1,061_CD 808_CD Capitalised_VBN software_NN and_CC other_JJ intangibles_NNS 106_CD 80_CD Other_JJ 12_CD 1_CD Deferred_JJ tax_NN IFRS_NNS adjustments_NNS above_IN 579_CD 362_CD other_JJ 111_CD 82_CD Total_JJ equity_NN under_IN IFRS_NNP 14,497_CD 11,168_CD Year_NN ended_VBD 31_CD Dec_NNP 2004_CD Profit_NN for_IN the_DT period_NN $_$ m_CD Profit_NN for_IN the_DT period_NN under_IN UK_NNP GAAP_NNP 3,831_CD Adjustments_NNP to_TO conform_VB to_TO IFRS_NNP Employee_NNP benefits_NNS 1_CD Financial_NNP instruments_NNS 163_CD Share-based_JJ payments_NNS 147_CD Goodwill_NNP 49_CD Capitalised_NNP software_NN and_CC other_JJ intangibles_NNS 21_CD Other_JJ 2_CD Deferred_JJ tax_NN IFRS_NNS adjustments_NNS above_IN 26_CD other_JJ 67_CD Profit_NN for_IN the_DT period_NN under_IN IFRS_NNP 3,683_CD Under_IN IAS_NNP 7_CD Cash_NNP Flow_NNP Statements_NNP ,_, movements_NNS on_IN cash_NN and_CC cash_NN equivalents_NNS are_VBP reconciled_VBN :_: under_IN UK_NNP GAAP_NNP the_DT statement_NN reconciles_VBZ cash_NN only_RB ._.
The_DT change_NN in_IN the_DT presentation_NN of_IN the_DT cash_NN flow_NN statement_NN under_IN IAS_NNP 7_CD makes_VBZ no_DT difference_NN to_TO the_DT free_JJ cash_NN generated_VBN by_IN the_DT Group_NNP ._.
IFRS_NNP TRANSITIONAL_NNP ARRANGEMENTS_NNPS AND_CC EARLY_NNP ADOPTION_NNP When_WRB preparing_VBG the_DT consolidated_JJ balance_NN sheet_NN under_IN IFRS_NNP at_IN 1_CD January_NNP 2003_CD ,_, the_DT date_NN of_IN transition_NN ,_, the_DT following_VBG optional_JJ exemptions_NNS from_IN full_JJ retrospective_JJ application_NN of_IN IFRS_NNP accounting_NN policies_NNS have_VBP been_VBN adopted_VBN :_: Business_NNP combinations_NNS the_DT provisions_NNS of_IN IFRS_NNP 3_CD have_VBP been_VBN applied_VBN prospectively_RB from_IN 1_CD January_NNP 2003_CD ._.
Business_NNP combinations_NNS that_WDT occurred_VBD before_IN 1_CD January_NNP 2003_CD have_VBP not_RB been_VBN restated_VBN ._.
Employee_NN benefits_NNS the_DT accumulated_VBN actuarial_JJ gains_NNS and_CC losses_NNS in_IN respect_NN of_IN employee_NN defined_VBN benefit_NN plans_NNS have_VBP been_VBN recognized_VBN in_IN full_JJ through_IN reserves_NNS at_IN 1_CD January_NNP 2003_CD ._.
Cumulative_JJ exchange_NN differences_NNS cumulative_JJ translation_NN differences_NNS on_IN net_JJ investments_NNS have_VBP been_VBN set_VBN to_TO zero_VB at_IN 1_CD January_NNP 2003_CD ._.
The_DT following_VBG optional_JJ exemptions_NNS from_IN full_JJ retrospective_JJ application_NN of_IN IFRS_NNP accounting_NN policies_NNS have_VBP not_RB been_VBN adopted_VBN :_: Fair_NNP value_NN or_CC revaluation_NN an_DT entity_NN may_MD elect_VB to_TO use_VB fair_JJ value_NN or_CC a_DT previous_JJ GAAP_NNP revaluation_NN at_IN the_DT opening_NN balance_NN sheet_NN date_NN ._.
This_DT exemption_NN did_VBD not_RB apply_VB to_TO AstraZeneca_NNP ._.
Compound_NN financial_JJ instruments_NNS If_IN the_DT compound_NN financial_JJ instruments_NNS are_VBP no_RB longer_RB outstanding_JJ at_IN the_DT date_NN of_IN transition_NN ,_, then_RB the_DT entity_NN is_VBZ not_RB required_VBN to_TO split_VB the_DT instrument_NN into_IN the_DT separate_JJ equity_NN and_CC liability_NN components_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC 138_CD Form_NN 20-F_JJ Information_NN 2005_CD EXPLANATION_NNP OF_IN TRANSITION_NNP TO_TO IFRS_NNP CONTINUED_VBD IFRS_NNS TRANSITIONAL_JJ ARRANGEMENTS_NNPS AND_CC EARLY_NNP ADOPTION_NNP CONTINUED_VBD In_IN addition_NN the_DT Group_NNP has_VBZ chosen_VBN to_TO restate_VB comparative_JJ information_NN with_IN respect_NN to_TO IAS_NNP 32_CD Financial_NNP Instruments_NNPS :_: Disclosure_NN and_CC Presentation_NN and_CC IAS_NNP 39_CD Financial_NNP Instruments_NNPS :_: Recognition_NN and_CC Measurement_NNP ._.
IFRS_NNS 2_CD Share-based_JJ Payments_NNS has_VBZ been_VBN adopted_VBN with_IN full_JJ retrospective_JJ application_NN ._.
The_DT Group_NNP has_VBZ also_RB adopted_VBN the_DT amendment_NN to_TO IAS_NNP 19_CD Employee_NNP Benefits_NNPS early_RB ,_, allowing_VBG actuarial_JJ gains_NNS or_CC losses_NNS to_TO be_VB recognized_VBN directly_RB in_IN the_DT consolidated_JJ statement_NN of_IN income_NN and_CC expense_NN in_IN the_DT period_NN in_IN which_WDT they_PRP arise_VBP ._.
Comparative_JJ information_NN has_VBZ been_VBN prepared_VBN on_IN this_DT basis_NN ._.
OTHER_JJ RECLASSIFICATIONS_NNS Phase_NN 4_CD post-launch_JJ trial_NN costs_NNS of_IN $_$ 388m_CD in_IN 2004_CD were_VBD reclassified_VBN to_TO selling_VBG ,_, general_JJ and_CC administrative_JJ costs_NNS from_IN research_NN and_CC development_NN as_IN part_NN of_IN the_DT transition_NN to_TO IFRS_NNP ._.
This_DT is_VBZ not_RB shown_VBN in_IN the_DT above_JJ reconciliations_NNS as_IN there_EX was_VBD no_DT profit_NN or_CC equity_NN impact_NN ._.
EFFECTS_NNS OF_IN IFRS_NNP IN_IN FINANCIAL_NNP STATEMENTS_NNP Employee_NN benefits_NNS IAS_NNP 19_CD requires_VBZ deficits_NNS and_CC surpluses_NNS in_IN company_NN pension_NN schemes_NNS to_TO be_VB recorded_VBN on_IN the_DT balance_NN sheet_NN ._.
IAS_NNP 19_CD also_RB requires_VBZ separate_JJ recognition_NN of_IN the_DT operating_NN and_CC financing_NN costs_NNS of_IN defined_VBN benefit_NN pensions_NNS and_CC other_JJ post-retirement_JJ employee_NN benefits_NNS in_IN the_DT income_NN statement_NN ._.
Actuarial_JJ gains_NNS and_CC losses_NNS are_VBP recognized_VBN in_IN full_JJ immediately_RB in_IN the_DT statement_NN of_IN recognized_VBN income_NN and_CC expense_NN and_CC cumulative_JJ actuarial_JJ gains_NNS and_CC losses_NNS at_IN 1_CD January_NNP 2003_CD have_VBP been_VBN recognized_VBN in_IN full_JJ as_IN an_DT adjustment_NN to_TO opening_VBG retained_VBN earnings_NNS ._.
Financial_NNP instruments_NNS IAS_NNP 32_CD sets_VBZ out_RP the_DT presentation_NN and_CC disclosure_NN requirements_NNS in_IN respect_NN of_IN financial_JJ instruments_NNS ,_, whilst_NN IAS_NNP 39_CD stipulates_VBZ the_DT measurement_NN and_CC recognition_NN requirements_NNS ._.
The_DT general_JJ principle_NN of_IN IAS_NNP 39_CD is_VBZ that_IN financial_JJ assets_NNS and_CC liabilities_NNS should_MD be_VB recognized_VBN at_IN fair_JJ value_NN ._.
AstraZeneca_NNP has_VBZ opted_VBN to_TO apply_VB the_DT financial_JJ instruments_NNS standards_NNS ,_, IAS_NNP 32_CD and_CC IAS_NNP 39_CD ,_, retrospectively_RB in_IN order_NN to_TO give_VB a_DT more_RBR meaningful_JJ view_NN of_IN the_DT Groups_NNS results_NNS and_CC financial_JJ position_NN ._.
Accounting_NN for_IN the_DT movements_NNS in_IN fair_JJ value_NN is_VBZ dependent_JJ on_IN the_DT designation_NN of_IN the_DT relevant_JJ financial_JJ instrument_NN ,_, with_IN movements_NNS going_VBG through_IN either_CC the_DT income_NN statement_NN and_CC or_CC being_VBG taken_VBN directly_RB to_TO equity_NN ._.
Share-based_JJ payments_NNS IFRS_VBP 2_CD requires_VBZ that_IN a_DT charge_NN is_VBZ recorded_VBN in_IN respect_NN of_IN shares_NNS and_CC share_NN options_NNS that_WDT are_VBP granted_VBN to_TO employees_NNS ._.
AstraZeneca_NNP has_VBZ recognized_VBN a_DT charge_NN to_TO income_NN representing_VBG the_DT fair_JJ value_NN of_IN outstanding_JJ employee_NN share_NN options_NNS granted_VBN to_TO approximately_RB 9,000_CD employees_NNS and_CC has_VBZ followed_VBN the_DT optional_JJ transitional_JJ arrangements_NNS which_WDT allow_VBP companies_NNS that_WDT have_VBP previously_RB disclosed_VBN the_DT fair_JJ value_NN charge_NN ,_, to_TO apply_VB IFRS_NNP 2_CD fully_RB retrospectively_RB to_TO all_DT options_NNS granted_VBN but_CC not_RB fully_RB vested_VBN at_IN the_DT relevant_JJ reporting_NN date_NN ._.
This_DT approach_NN is_VBZ encouraged_VBN in_IN the_DT standard_NN and_CC gives_VBZ a_DT better_JJR indication_NN of_IN how_WRB past_JJ results_NNS are_VBP affected_VBN by_IN IFRS_NNP 2_CD ._.
Business_NN combinations_NNS IFRS_VBP 3_CD prohibits_VBZ merger_NN accounting_NN and_CC the_DT amortisation_NN of_IN goodwill_NN ._.
The_DT standard_JJ requires_VBZ goodwill_NN to_TO be_VB carried_VBN at_IN cost_NN with_IN impairment_NN reviews_NNS both_DT annually_RB and_CC also_RB when_WRB there_EX are_VBP indications_NNS that_IN the_DT carrying_VBG value_NN may_MD not_RB be_VB recoverable_JJ ._.
Under_IN the_DT transitional_JJ arrangements_NNS of_IN IFRS_NNP 1_CD a_DT company_NN has_VBZ the_DT option_NN of_IN applying_VBG IFRS_NNP 3_CD prospectively_RB from_IN the_DT transition_NN date_NN to_TO IFRS_NNP ._.
AstraZeneca_NNP has_VBZ chosen_VBN this_DT option_NN rather_RB than_IN to_TO restate_VB all_DT previous_JJ business_NN combinations_NNS including_VBG accounting_NN for_IN the_DT merger_NN of_IN Astra_NNP and_CC Zeneca_NNP ._.
The_DT impact_NN of_IN IFRS_NNP 3_CD and_CC associated_VBN transitional_JJ arrangements_NNS on_IN AstraZeneca_NNP are_VBP as_IN follows_VBZ :_: All_DT prior_JJ business_NN combination_NN accounting_NN is_VBZ frozen_VBN at_IN the_DT transition_NN date_NN ._.
The_DT value_NN of_IN goodwill_NN is_VBZ frozen_VBN at_IN 1_CD January_NNP 2003_CD and_CC amortisation_NN previously_RB reported_VBN under_IN UK_NNP GAAP_NNP for_IN 2003_CD and_CC 2004_CD is_VBZ removed_VBN ._.
Dividends_NNS IAS_NNP 10_CD requires_VBZ dividends_NNS to_TO be_VB recognized_VBN as_IN a_DT liability_NN when_WRB they_PRP are_VBP declared_VBN ._.
For_IN the_DT final_JJ dividend_NN this_DT is_VBZ usually_RB after_IN the_DT accounting_NN period_NN to_TO which_WDT it_PRP relates_VBZ ,_, when_WRB the_DT dividend_NN is_VBZ approved_VBN by_IN the_DT Board_NNP ._.
Consequently_RB there_EX is_VBZ an_DT adjustment_NN to_TO remove_VB the_DT liability_NN for_IN the_DT final_JJ dividend_NN declared_VBD post_NN year_NN end_NN ._.
Capitalised_VBN software_NN and_CC other_JJ intangibles_NNS IAS_NNP 38_CD requires_VBZ all_DT intangible_JJ assets_NNS that_WDT meet_VBP the_DT capitalization_NN criteria_NNS to_TO be_VB capitalized_VBN ._.
For_IN AstraZeneca_NNP ,_, this_DT led_VBD to_TO the_DT following_VBG Group_NNP policies_NNS being_VBG applied_VBN :_: In_IN respect_NN of_IN internal_JJ product_NN development_NN expenditure_NN ,_, it_PRP is_VBZ managements_NNS view_VBP that_IN it_PRP is_VBZ not_RB possible_JJ to_TO demonstrate_VB with_IN sufficient_JJ certainty_NN that_IN ,_, prior_RB to_TO regulatory_JJ approval_NN ,_, these_DT criteria_NNS are_VBP met_VBN ._.
Consequently_RB ,_, AstraZeneca_NNP would_MD not_RB expect_VB to_TO capitalize_VB internal_JJ development_NN costs_NNS ._.
In_IN respect_NN of_IN internal_JJ development_NN expenditure_NN on_IN software_NN ,_, it_PRP is_VBZ managements_NNS view_VBP that_IN some_DT projects_NNS have_VBP met_VBN the_DT criteria_NNS for_IN capitalization_NN ._.
Results_NNS have_VBP been_VBN adjusted_VBN to_TO include_VB both_DT the_DT capitalized_JJ costs_NNS and_CC associated_VBN amortisation_NN of_IN these_DT projects_NNS ._.
The_DT standard_JJ requires_VBZ all_DT externally_RB acquired_VBN intangibles_NNS to_TO be_VB capitalized_VBN and_CC the_DT results_NNS have_VBP been_VBN adjusted_VBN to_TO recognize_VB a_DT small_JJ number_NN of_IN products_NNS in_IN early_JJ phase_NN development_NN that_WDT had_VBD been_VBN expensed_VBN under_IN UK_NNP GAAP_NNP ._.
Deferred_JJ taxation_NN IAS_NNP 12_CD requires_VBZ deferred_JJ tax_NN to_TO be_VB calculated_VBN using_VBG the_DT purchasers_NNS tax_NN rate_NN instead_RB of_IN the_DT vendors_NNS tax_NN rate_NN under_IN UK_NNP GAAP_NNP ,_, changing_VBG the_DT methodology_NN used_VBN to_TO calculate_VB deferred_JJ tax_NN on_IN unrealised_JJ profit_NN on_IN intra-group_JJ sales_NNS ._.
The_DT standard_JJ further_JJ requires_VBZ a_DT deferred_JJ tax_NN provision_NN for_IN all_DT rolled_VBN over_IN capital_NN gains_NNS rather_RB than_IN those_DT expected_VBN to_TO crystallise_NN ._.
